Company: APXIF
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065703
Chunk: 46

Company: APx Acquisition Corp. I
Filing Date: 2025-07-18
Form: F-4/A
Chunk 46
---
 QUESTIONS AND ANSWERS ABOUT THE BUSINESS COMBINATION AND THE SPECIAL MEETIN G The following questions and answers briefly address some commonly asked questions about the proposals to be presented at the special meeting of shareholders, including with respect to the proposed Business Combination. The following questions and answers may not include all the information that is important to SPAC Shareholders. Shareholders are urged to read carefully this entire proxy statement / prospectus, including the financial statements and annexes attached hereto and the other documents referred to herein. Q:What is the Business Combination? A:APx, OmnigenicsAI and Merger Sub have entered into the Business Combination Agreement, dated as of March 25, 2024, pursuant to which, among other things, Merger Sub will merge with and into APx (with APx being the surviving company and a direct wholly -ownedsubsidiary of OmnigenicsAI) in exchange for shareholders of APx receiving merger consideration consisting of Company Shares and warrants to purchase Company Shares: APx will hold the Special Meeting to, among other things, obtain the approvals required for the Business Combination and the other transactions contemplated by the Business Combination Agreement and you are receiving this proxy statement/prospectus in connection with such meeting. See “ The Business Combination Agreement” beginning on page 139. In addition, a copy of the Business Combination Agreement is attached to this proxy statement/prospectus as Annex A. Q:Why am I receiving this proxy statement? A:APx is sending this proxy prospectus to its shareholders to help them decide how to vote their shares of APx ordinary shares with respect to the matters to be considered at the Special Meeting. The Business Combination cannot be completed unless APx’s shareholders approve the Business Combination Proposal and the Cayman Merger Proposal set forth in this proxy statement/prospectus for their approval. Information about the Special Meeting, the Business Combination and the other business to be considered by shareholders at the Special Meeting is contained in this proxy statement/prospectus. This document constitutes a proxy statement of APx and a prospectus of OmnigenicsAI. It is a proxy statement because the APx Board is soliciting proxies using this proxy statement/prospectus from its shareholders. It is a prospectus because OmnigenicsAI, in connection with the Business Combination, is offering Company Shares and Warrants in exchange for APx’s outstanding SPAC Class A Ordinary Shares and warrants. See “ The Business Combination Agreement — Consideration to be Received in the Business Combination.” YOUR VOTE